title: Matrix metalloproteinase 13: a potential intermediate between low expression of microRNA-125b and increasing metastatic potential of non-small cell lung cancer.
abstract: Recent findings have suggested that microRNAs may be involved in the regulation of metastasis in malignant cancers such as non-small cell lung cancer (NSCLC). This study aimed to determine the relationship between expression of miR-125b and matrix metalloproteinase 13 (encoded by MMP-13) and the metastatic potential of cancer cells in NSCLC. Expression levels of miR-125b transcripts and MMP-13 proteins were analyzed by quantitative real-time PCR and immunohistochemistry, respectively, in tumor tissues and adjacent nontumor tissues from 42 patients with NSCLC. The interaction between miR-125b and MMP-13 expression and the associations between miR-125b and clinicopathologic data were analyzed. MiR-125 b expression levels were decreased in NSCLC tumor tissue samples, which correlated with an increased incidence of lymph node metastases, increased pathologic stage, increased MMP-13 expression levels, and decreased early progression-free survival. Additionally, we have demonstrated that increased levels of miR-125b can directly downregulate MMP-13 protein expression and inhibit the invasive capabilities of cancer cells. Expression levels of miR-125b were negatively correlated with metastatic potential of NSCLC tumors, which may function through regulation of MMP-13.
authors.affiliation: Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; National Clinical Research Center of Cancer, China; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China; Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
authors.forename: Xiaozhou
authors.initials: X
authors.lastname: Yu
authors.affiliation: Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; National Clinical Research Center of Cancer, China; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Wei
authors.affiliation: Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; National Clinical Research Center of Cancer, China; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
authors.forename: Jinpu
authors.initials: J
authors.lastname: Yu
authors.affiliation: Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; National Clinical Research Center of Cancer, China; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
authors.forename: Hua
authors.initials: H
authors.lastname: Zhao
authors.affiliation: Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; National Clinical Research Center of Cancer, China; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Jia
authors.affiliation: Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; National Clinical Research Center of Cancer, China; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
authors.forename: Yingnan
authors.initials: Y
authors.lastname: Ye
authors.affiliation: Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; National Clinical Research Center of Cancer, China; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
authors.forename: Ruijuan
authors.initials: R
authors.lastname: Du
authors.affiliation: National Clinical Research Center of Cancer, China; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China; Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. Electronic address: renxiubao@tjmuch.com.
authors.forename: Xiubao
authors.initials: X
authors.lastname: Ren
authors.affiliation: Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; National Clinical Research Center of Cancer, China; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China. Electronic address: lihui@tjmuch.com.
authors.forename: Hui
authors.initials: H
authors.lastname: Li
mesh_terms: D000328:Adult; D002289:Carcinoma, Non-Small-Cell Lung / Q000556:secondary*; D045744:Cell Line, Tumor; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology*; D008207:Lymphatic Metastasis; D008297:Male; D053509:Matrix Metalloproteinase 13 / Q000502:physiology*; D035683:MicroRNAs / Q000502:physiology*; D008875:Middle Aged; D009367:Neoplasm Staging
chemical_list: C531888:MIRN125 microRNA, human; D035683:MicroRNAs; C507079:MMP13 protein, human; D053509:Matrix Metalloproteinase 13
keywords: NSCLC; matrix metalloproteinase 13; miR-125b; non–small cell lung cancer; tumor metastasis